Abstract
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
All Keywords
【초록키워드】 COVID-19, clinical trial, severity, sera, Patient, SARS-CoV-2 antigen, neutralizing monoclonal antibody, populations, Prevent, the disease, determine, reduce, 【제목키워드】 COVID-19, Treatment, antibody,
【초록키워드】 COVID-19, clinical trial, severity, sera, Patient, SARS-CoV-2 antigen, neutralizing monoclonal antibody, populations, Prevent, the disease, determine, reduce, 【제목키워드】 COVID-19, Treatment, antibody,
{{{ 추상적인 }}}
COVID-19 회복기 환자의 혈청과 SARS-CoV-2 항원에 특이적인 단일클론항체를 중화하는 것이 COVID-19를 예방하거나 고위험군에서 질병의 중증도를 감소시킬 수 있는지 여부를 결정하기 위해서는 더 많은 임상 시험 데이터가 필요합니다.